Completed PHASE3 INTERVENTIONAL 2-arm NCT01355627

TASALL - TachoSil® Against Liquor Leak

TachoSil® Versus Current Practice in Dura Sealing Techniques for the Prevention of Post-operative Cerebrospinal Fluid (CSF) Leaks in Patients Undergoing Skull Base Surgery: An Open Label, Randomised, Controlled, Multi-centre, Parallel Group Efficacy and Safety Trial.

Sponsor: Takeda

Conditions Cerebrospinal Fluid Leaks

Interventions Current Practice TachoSil®

Updated 6 times since 2017 Last updated: Jun 26, 2014 Started: Apr 30, 2011 Primary completion: Jun 30, 2013 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01355627, this PHASE3 trial focuses on Cerebrospinal Fluid Leaks and remains completed. Sponsored by Takeda, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Barcelona, Spain , Brussels, Belgium , Dammers, Netherlands , El Palmar, Spain , Freiburg im Breisgau, Germany , Gdansk, Poland , Genk, Belgium , Genova, Italy , Gothenburg, Sweden and 26 more locations